Danish pharmaceutical company Novo Nordisk has announced plans to invest an additional 200 million yuan (US$29.4 million) in its production facility in Tianjin, China, expanding both drug manufacturing and injection pen assembly capacity, Xinhua reports.
The expansion will increase production capacity and improve supply efficiency as demand for medicines continues to grow in the Chinese market, the company said.
Located in the Tianjin Economic-Technological Development Area, the facility serves as one of Novo Nordisk’s key global manufacturing hubs, supplying injection devices and finished pharmaceutical products to China and other markets.
According to Executive Vice President, Kasper Bødker Mejlvang, the investment reflects Novo Nordisk’s long-term commitment to China and its strategy of producing innovative products locally.
Novo Nordisk entered China in 1994 and has steadily expanded its presence in the country. Since 2003, the company has invested more than 17 billion yuan in China.
